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The molecular investigation of head and neck cancer
targets requires the utilization and optimization of
established animal models to characterize the effects of
gene transcription and protein expression on invasion
and metastasis. Floor-of-the-mouth murine models have
been developed to study tumor growth, invasion, and
metastasis of murine squamous cell carcinoma (SCC)
cells in immunocompetent mice and invasion and meta-
stasis of human SCC cells in nude mice. However, there
are tumor cell lines that do not produce tumors in mice,
using standard techniques, thus reducing the utility of the
model to study specific genetic or treatment conditions.
Furthermore, these techniques require large tumor vol-
umes raising the possibility of airway compromise. In this
report, we detail significant modifications to the ortho-
topic floor-of-mouth murine model for human SCC to
facilitate predictable growth of a large panel of University
of Michigan SCC cell lines. Furthermore, we describe the
use of bioluminescence and micro-computed tomogra-
phy to monitor tumor growth and bony invasion.
J Oral Pathol Med (2007) 36: 363–70
Keywords: murine; orthotopic; SCC
Introduction
Head and neck squamous cell carcinoma (HNSCC) has
a survival rate of <50%, a prognosis that is poorer
than breast or colon cancer or melanoma (1). This poor
prognosis is due to two confounding issues: late
detection of HNSCC and inadequate treatment options
for advanced disease (2). Identification of the molecular
events that regulate the pathogenesis, progression, and
treatment response of HNSCC will provide objective
markers and specific treatment targets, thereby redu-
cing the morbidity of the disease. The molecular
investigation of a disease process is greatly enhanced
by reliable animal models that replicate the human
disease. In this regard, murine models for oral cancer
have facilitated investigation of HNSCC (3–5). Xeno-
graft tumor models involve injection and growth of
tumor cells in the subcutaneous tissue of the hind leg or
nape of mice (6). However, these models do not
replicate the locoregional biology of the tumor, an
important element of human HNSCC, which grows in
proximity to abundant vasculature and bone.
These drawbacks were addressed by orthotopic, floor-
of-mouth murine models which facilitate studies on
tumor growth, invasion, and metastasis of murine
squamous cell carcinoma (SCC) cells in immunocom-
petent mice (3) and invasion and metastasis of human
SCC cells in immunodeficient mice (4, 5, 7). However,
we observed that the model is effective only for specific
HNSCC cell lines. A robust model is essential to study
multiple HNSCC cell lines that may represent different
genetic mutations, thereby facilitating pre-clinical stud-
ies that are relevant to multiple HNSCCs. Low tumor
injection volume and tumor cell dose minimize the
potential for airway compromise and facilitate long-
term tumor growth in vivo, respectively. Hence, the
murine model for human HNSCC was modified and
optimized to address these problems. Using a matrigel
basement membrane matrix in this model, tumor
induction is successful even with challenging HNSCC
cell lines; the incidence of injection-induced mortalities
is low, and in the initial stages of tumor development,
tumor cells are restricted to a small area, thereby
reducing tumor cell dose. The prolonged duration of
tumor growth from this small cell innoculum allows
development of metastases. Furthermore, SCC cells
were labeled with a luciferase reporter and tumor
growth and bone invasion were assayed by biolumin-
escence and micro-computed tomography (lCT),
respectively. This floor-of-the-mouth human oropha-
ryngeal SCC model is valuable for correlation of in vitro
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data with in vivo studies on tumor progression and to
evaluate potential chemotherapeutic agents.
Materials and methods
Cell culture
UM-SCC-(1, 17A, 17B, 22A, 22B, 74A, 81B, 11A, 11B,
14A, 5) and OSCC3 head and neck SCC cell lines were
cultured, as described previously (8, 9), in Dulbecco’s
modified Eagle’s medium (DMEM, GIBCO, Grand
Island, NY, USA) containing 10% fetal bovine serum,
penicillin 100 U⁄ml, streptomycin 100 lg⁄ml, and
50 lg⁄ml L-glutamine.
Immunodeficient mouse tumor model
All protocols for in vivo studies were approved by the
University Committee on the Use and Care of Animals
at the University of Michigan.
HNSCC cell lines were grown to 70% confluence
prior to injection. Six-week-old athymic nude mice
(NCr-nu⁄nu strain, NCI, Frederick, MD, USA, weight
18–25 gm) were anesthetized via intraperitoneal injec-
tion with 100 mg⁄kg ketamine and 10 mg⁄kg xylazine.
SCC cells were suspended in 0.2 ml of DMEM and
injected submucosally in the floor of the mouth. UM-
SCC-11B cells were suspended in 0.02–0.2 ml DMEM
prior to injection. The animals were killed and the
primary tumor and adjacent tissues, lungs, and liver
were harvested, rinsed in phosphate buffered saline
(PBS) and fixed overnight in 10% buffered formalin.
The tissue was paraffin-embedded, sectioned, and
stained with hematoxylin and eosin. Samples containing
bone were decalcified in 10% EDTA (pH 7.4) prior to
sectioning.
Matrigel technique
UM-SCC-5 and UM-SCC-11A cells in DMEM, were
chilled on ice, and suspended in an equal volume of
Matrigel (BD Biosciences, San Jose, CA, USA) basement
membrane matrix in the presence or absence of growth
factors (EGF, bFGF, NGF, PDGF, IGF-1, TGF-b) at a
final concentration of 1 · 105–2 · 106 cells⁄0.1 ml,
respectively. The cell⁄matrigel solution was chilled on
ice prior to the floor-of-mouth injection.
Live imaging – bioluminescence
To assess SCC cell growth and tumor burden in vivo by
bioluminescence, UM-SCC-11B (2.5 · 105) was stably
co-transfected with the human proximal promoter con-
taining 1974 bp of 5¢-flanking sequence of the receptor
activator for nuclear factor j B ligand (RANKL) gene in
reporter plasmid pGL3-Basic and pcDNA3.1, contain-
ing a mammalian selection marker to generate stably
transfected clones (Invitrogen, Carlsbad, CA, USA).
In vivo real-time RANKL promoter activity was assessed
by bioluminescence following intraperitoneal injection
of D-luciferin substrate at 40 mg⁄ml of luciferin substrate
in PBS at a dose of 150 mg⁄kg body weight essentially, as
described previously (10) using the Xenogen IVIS
imaging system (Xenogen Corp., Alamenda, CA, USA)
every 2 weeks over an 8-week period. Subsequently,
animals were euthanized and the mandibles were disar-
ticulated at the level of the condyle using a diamond-
separating disk. Block sections were immersed directly in
10% buffered formalin for at least 72 h.
Micro-computed tomography
Non-demineralized rat maxillae were scanned in 70%
ethanol by a cone beam lCT system (GE Healthcare
BioSciences). Each scan was reconstructed at a mesh size
of 18 · 18 · 18 lm and three-dimensional digitized
images were generated for each specimen. Using GEHC
MicroView software (version Viz+ 2.0 build 0029 GE
Healthcare BioSciences), the images were rotated into a
standard orientation and threshold to distinguish
between mineralized and non-mineralized tissue. For
each specimen, a grayscale voxel value histogram was
generated to determine an optimal threshold value. Loss
of bone volume caused by local invasion of HNSCC
into the mandible was assessed using three-dimensional
isoform displays. After proper image orientation, the
region of interest (ROI) was determined. The standard
ROI (volumetric box of 250 · 200 · 200 pixels) was
used from the inferior alveolar foramen. After estab-
lishing the threshold at 1621, the bone volume fraction
was calculated as the percent of bone within the ROI.
Results
Optimization of xenograft mouse model of human head
and neck squamous cell carcinoma
The murine floor-of-mouth model for human oral
cancer was optimized for xenografts using several SCC









UM-SCC-1 1 2 0
UM-SCC-17A 2 4 0
UM-SCC-17B 0.5 6 1
1 17 2
2 5 1
UM-SCC-22A 1 14 1
UM-SCC-22B 0.5 4 0
1 10 0
UM-SCC-74A 2 6 0
UM-SCC-81B 1 6 1






OSCC3 1 2 0
2 2 0
UM-SCC-14A 1 0 2
2 0 2
UM-SCC-5a 0.5 2 0
1 2 0
2 2 0
UM-SCC-11Aa 0.1 2 0
0.5 2 0
aCell lines requiring matrigel.
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cell lines, UM-SCC-(11A, 11B, 17A, 17B, 1, 5, 74A,
81B, 22A, 22B) and OSCC3. The tumor cell dose,
number of positive takes, and number of failures are
shown in Table 1. Tumor cell dose was optimized for
each cell line to produce 4–5 mm tumors, corresponding
to a palpable tumor volume of 35–60 mm3, within 2–
4 weeks post-injection. UM-SCC-17B xenografts exhib-
ited morphologic and cytologic features compatible with
poorly differentiated HNSCC consistent with the nature
of the recurrent tumor from which this cell line was
developed (9, 10). UM-SCC-17B (Fig. 1A, B) exhibited
islands and sheets of malignant epithelial cells exhibiting
nuclear hyperchromatism, nuclear pleomorphism, and
numerous atypical mitoses (1B, arrows). Similar histo-
pathologic features were observed with other HNSCC
cell lines (UM-SCC-22A, UM-SCC-74A, OSCC3).
Additionally, microscopic examination of the liver
(Fig. 1C, D) and lung (Fig. 1E) showed atypical mitoses
(arrows) and nuclear pleomorphism (arrowheads) at







Figure 1 Tumors are produced in the floor of the mouth, 3 weeks post-injection of UM-SCC-17B cells. (A, B) Primary oral tumor. (C, D)
Metastatic tumor in the liver. (E) Occasional neoplastic cells were observed in the lung. Pleomorphic neoplastic cells are observed in the liver (C, D)
and lung (E) (arrowheads). A typical mitoses are indicated by arrows.
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Matrigel facilitates tumorigenesis of squamous cell
carcinoma cells
Despite the large panel of HNSCC cells that were
tumorigenic in mice, other cell lines such as UM-SCC-
5 and UM-SCC-11A did not grow in the floor of
mouth (up to 5 · 106 cells). As these SCC cell lines
vary in genetic mutations and chemotherapy resistance
(11), a more robust murine model of HNSCC is
essential. Hence, these cell lines were suspended in a
basement membrane matrix. The matrix forms a gel at
body temperature, thereby facilitating localization of
tumor cells. UM-SCC-5 and UM-SCC-11A (0.5–
2 · 106 and 0.1–0.5 · 106 cells, respectively) induced
tumors in 3–4 weeks following injection. UM-SCC-5
tumors exhibited invasion of sheets and nests of
poorly differentiated tumor cells into the surrounding
tissues (Fig. 2A) and the lung (Fig. 2B). The histology
is consistent with the original tumor pathology report
that described the surgical specimen used to establish
this cell line as poorly differentiated squamous cell
carcinoma’. Tumor islands (Fig. 2C, D, arrows) of
UM-SCC-11A exhibited keratin pearl formation, nuc-
lear hyperchromatism and pleomorphism and invaded
skeletal muscle (Fig. 2C, arrowheads) and bone
(Fig. 2D). Tumor islands invading the surrounding
structures were also observed with UM-SCC-5A (data
not shown). Thus, the Matrigel modification technique
can be used to support in vivo tumor development
with cell lines that typically do not grow with standard
procedures.
Live imaging of tumor growth
The proximal promoter of the human RANKL gene
was used to induce expression of a luciferase reporter to
follow in vivo expression of luciferase in implanted UM-
SCC-11B cells. Thus, reporter activity could be used to
monitor in vivo expression and tumor burden. Using this
approach, UM-SCC-11B-RANKL-Luc cells were injec-
ted into floor of the mouth (0.25 · 106 cells; n = 6) of
athymic (nu ⁄nu SCID) mice. To identify tumor growth,
radiographs of the head and neck region at 2, 6, and
8 weeks post-tumor injection were taken (Fig. 3A).
Radiographic changes, including osteolytic changes
and soft tissue tumor growth, were not identified until
6 weeks after UM-SCC-11B-RANKL-Luc cell injec-
tion. The changes were readily evident at 8 weeks.
Tumor was easily identifiable as early as 2 weeks by
visual examination, palpation, and using biolumines-
cence imaging (BLI) and increased every 2 weeks until





Figure 2 Matrigel facilitates tumor induction with cell lines that are otherwise non-tumorigenic. UM-SCC-5 (1 · 106) and UM-SCC-11A
(0.1 · 106) cells were suspended in Matrigel and injected into the floor of the mouth. Primary (A) and metastatic (B) tumors were identified with
UM-SCC-5. UM-SCC-11A islands (arrows) exhibited skeletal muscle (C, arrowheads) and bone invasion (D).
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as shown in Fig. 3C. These data indicate that BLI can
be used to non-invasively measure SCC tumor growth in
the floor of the mouth.
Micro-computed tomography permits three-dimensional
visualization of tumor–bone interaction
Following killing, non-decalcified specimens were
scanned by lCT. Three-dimensional isoform images
(Fig. 4) indicate extensive bone destruction (lower
panel) compared with non-tumor control specimen
(upper panel). In addition, note that molar teeth appear
to be lost because of extensive bone loss in this model.
Histology confirms the presence of local invasion of
oral cancer in the floor-of-mouth model. The mandible
and adjacent tissues were harvested and decalcified.
Sections through the tongue, floor of mouth, and
mandible confirmed the presence of an aggressive malig-
nant epithelial infiltrate (Fig. 5A, B) that had invaded
bone (Fig. 5D, C, F, arrows) and extended to the tooth
surface (Fig. 5D–F). As expected, SCC cells were present
in the floor of the mouth and had invaded adjacent
structures (Fig. 5A, arrow), underscoring the importance
of this model in replicating the human disease.
Discussion
Any investigation of the etiology and pathogenesis of a
disease requires in vivo models that recapitulate the
disease. Furthermore, the development of new drug and
therapeutic regimens to combat head and neck cancer
requires pre-clinical testing using murine models. Exist-
ing tumor models often require injection of tumor cells
into the flank or nape of mice, and therefore do not
accurately recapitulate the vasculature, mucosa, muscu-
lature, and nerves of the upper aerodigestive tract. Head




Figure 3 Tumor growth can be monitored by Faxitron X-ray and bioluminescence. UM-SCC-11B-RANKL-Luc reporter cells (0.25 · 106) were
injected into the floor of the mouth and tumor growth was monitored over an 8-week period. (A) Faxitron X-rays from 2-, 6-, and 8-week time
points indicate tumor growth (see arrow) and loss of mineralization consistent with tumor invasion of mandible. (B) Representative
bioluminescence images of mice over the 2- to 8-week time frame. The same mouse is shown over this time period. Color bar indicates luminescence
intensity from low (blue) to high (red). (C) Graphical representation of photon counts of bioluminescence data obtained from three animals over
8-week time period. Luminescence emitted from each mouse was integrated over 1-min exposure starting 10 min after D-luciferin injection.
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locoregional aggressiveness associated with direct exten-
sion into cervical structures, and thus requires a model
that more closely recapitulates the natural progression
of the disease (4, 7). This point is illustrated quite nicely
by Kawashiri and colleagues, who injected 152 nude
mice intra-orally and subcutaneously on the back with
two established oral SCC cell lines, OSC-19 and OSC-20
(12). They described the back tumors, histologically and
on gross dissection, as having a more expansive but
poorly invasive growth pattern. In contrast, tumors
derived from SCC cells implanted in the floor of the
mouth were histologically similar to the original tumors
and were significantly more invasive in surrounding
tissues (12). In the present study, we observed highly
aggressive HNSCCs, similar in histology to the human
HNSCCs from which they were established.
Despite the apparent advantages of a floor-of-mouth
approach to study head and neck cancer, a number of
significant challenges existed with previous models.
First, techniques using human SCC cells required large
numbers of cells (typically 2.0 · 106 cells) to obtain a
critical mass’ of cells sufficient to produce tumors (7).
This large number of cells, however, sometimes results
in very large tumors, and killing of the animals at
2 weeks post-injection becomes necessary. Therefore,
these models are precluded from being used for long-
term drug efficacy studies. Because previous laboratories
used relatively large volumes of Hanks buffered saline
for the cell suspensions, it is reasonable to speculate that
large numbers of cells were necessary because of
inevitable leakage and loss of cells. For example, Simon
and colleagues reported relatively large injection vol-
umes into the floor of the mouth, at a depth superficial
to the mylohyoid muscle (7). In contrast, we were able to
obtain tumors with as few as 0.25 · 106 human SCC
cells (Fig. 5) suspended in a much smaller volume of
0.2 ml of plain DMEM, and were able to follow these
animals 8 weeks after injection. Thus, we developed a
strategy whereby we could predictably grow tumors in
the floor of the mouth of nude mice for a long period of
time and with low tumor cell suspension volume and
tumor cell dose. Furthermore, using bioluminescence
and lCT, tumor growth, and bone invasion can be
monitored in vivo.
Our optimized technique resulted in successful tumor
growth using 10 different human SCC cell lines; UM-
SCC-(1, 11B, 17A, 17B, 74A, 81B, 22A, 22B) and
OSCC3 cells. Despite this success, however, there were
some cells that did not produce tumors using our
optimized or standard injection techniques. The inabil-
ity to grow certain cell lines using the model significantly
limits its utility for those investigators that must use a
particular cell line for reasons specific to their research.
For example, the UM-SCC-5 (parental) and UM-SCC-
5PT (cisplatin resistant) cell lines have been used to
study cisplatin resistance in vitro(11), and could also
serve as an effective model system to study chemother-
apy effectiveness and synergy in vivo. The UM-SCC-5
or UM-SCC-11A cell lines did not grow in the floor-of-
mouth model using standard procedures. However, by
embedding 0.5–2 · 106 or 0.1–0.5 · 106 cells, respect-
ively, in Matrigel, we were able to obtain palpable
tumors at 2–4 weeks post-injection.
The Matrigel preparation mimics natural basement
membrane in that it contains type IV collagen and
laminin, as well as proteases (MMP-2, MMP-9, plasmi-
nogen activator) (13). It may also contain growth
factors (EGF, bFGF, NGF, PDGF, IGF-1, TGF-b),
sulfated macromolecules, and glycosylated molecules
(13). The exact mechanism by which Matrigel promotes
SCC cell growth is not known; however, it is plausible
that the angiogenic and growth factors embedded in the
Matrigel provides a microenvironment that is condu-
cive to the establishment of solid tumors (13, 14).
Additionally, cells embedded in Matrigel become
Figure 4 Micro-CT shows local tumor invasion in the mandible.
UM-SCC-11B-RANKL-Luc reporter cells (0.25 · 106) were injected
into the floor of the mouth. Eight-week post-injection mice were killed
for lCT imaging. Representative reformatted lCT isoform displays
from saline-injected (upper panel) and tumor-injected (lower panel)
mice. Arrows indicate tooth and bone loss in tumor-injected animals.
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Figure 5 Tumor growth was apparent in the floor of the mouth (A, B; F of M). The tumor islands destroyed bone (B, C, D, F) and extended to the
enamel surface (E).
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polarized and also remain in closer proximity to each
other than in a buffer solution, which could also serve
to increase the locoregional level of angiogenic and
growth factors as a result of autocrine and paracrine
release (13).
Receptor activator for nuclear factor j B ligand is an
essential cytokine required for full osteoclast maturation
and activation (15, 16). Initial studies indicated that
stably transfected UM-SCC-11B cells harboring this
plasmid express high levels of luciferase reporter in vitro.
Hence, these cells were used to monitor tumor growth
by bioluminescence in vivo. Recent evidence suggest
tumor invasion and osteolytic activity requires RANKL
(15), but this question is still in debate with oral SCC
(17) and was not investigated in the present study.
In vitro findings suggest that all SCC cell lines express
RANKL (data not shown). In the present study, bone
invasion was observed even in the absence of exogenous
RANKL (Fig. 2D).
As a result of significant modifications, we have made
this floor-of-the-mouth human oropharyngeal cancer
model more effective for in vivo studies on tumor
progression and for the evaluation of potential chemo-
therapeutic agents (18).
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